Trials / Completed
CompletedNCT01517009
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Jeroen Bosch Ziekenhuis · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the feasibility of chemotherapy, consisting of docetaxel, cisplatin and capecitabine given prior to surgery for stomach cancer. Furthermore, an extended type of removal of lymph nodes will be implemented.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | 60 mg/m2, 1 gift every 3 weeks, in total 4 gifts |
| DRUG | cisplatin | 60 mg/m2, one gift every three weeks, in total 4 gift |
| DRUG | Capecitabine | 1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles |
| PROCEDURE | D1extra-resection | An extended lymphadenectomy compared to a D1 resection for gastric cancer |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2012-11-01
- Completion
- 2013-05-01
- First posted
- 2012-01-25
- Last updated
- 2013-06-26
Locations
5 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01517009. Inclusion in this directory is not an endorsement.